ES2178750T3 - 17-beta- iclopropil(amino/oxi)4-aza esteroides como inhibidores activos de la 5-alfa-reductasa y de c17-20-liasa de testosterona. - Google Patents

17-beta- iclopropil(amino/oxi)4-aza esteroides como inhibidores activos de la 5-alfa-reductasa y de c17-20-liasa de testosterona.

Info

Publication number
ES2178750T3
ES2178750T3 ES97901995T ES97901995T ES2178750T3 ES 2178750 T3 ES2178750 T3 ES 2178750T3 ES 97901995 T ES97901995 T ES 97901995T ES 97901995 T ES97901995 T ES 97901995T ES 2178750 T3 ES2178750 T3 ES 2178750T3
Authority
ES
Spain
Prior art keywords
compounds
liasa
aza
testosterona
iclopropil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97901995T
Other languages
English (en)
Inventor
James R Pribish
Cynthia A Gates
Philipp M Weintraub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2178750T3 publication Critical patent/ES2178750T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A 4 - AZA - 17 BE - (CICLOPROPOXI) ANDROST - 5 AL - ANDROSTAN - 3 - ONA, 4 - AZA - 17 BE (CI CLOPROPILAMINO) - ANDROST - 4 - EN - 3 - ONA Y A COMPUESTOS RELACIONADOS Y A COMPOSICIONES QUE COMPRENDEN ESTOS COMPUESTOS, ASI COMO LA INHIBICION DE LIASA C 17-20), 5 AL - REDUCTASA Y C 17 AL - HIDROLASA Y AL USO DE ESTOS COMPUESTOS EN EL TRATAMIENTO DE TRASTORNOS MEDIADOS POR ANDROGENOS Y ESTROGENOS, INCLUIDA LA HIPERPLASIA PROSTATICA BENIGNA, CANCER DE PROSTATA MEDIADO POR ANDROGENOS, CANCER DE MAMA MEDIADO POR ESTROGENOS Y A TRASTORNOS MEDIADOS POR DHT TALES COMO EL ACNE. TAMBIEN SE INCLUYEN LOS TRASTORNOS RELATIVOS A LA SOBRESINTESIS DE CORTISOL, POR EJEMPLO, EL SINDROME DE CUSHING. EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE ANDROGENOS TAMBIEN COMPRENDE UNA TERAPIA COMBINATORIA CON ANTAGONISTAS CONOCIDOS DEL RECEPTOR DE ANDROGENOS, TALES COMO LA FLUTAMIDA. LOS COMPUESTOS DE LA INVENCION TIENEN LA FORMULA GENERAL (I).
ES97901995T 1996-02-14 1997-01-09 17-beta- iclopropil(amino/oxi)4-aza esteroides como inhibidores activos de la 5-alfa-reductasa y de c17-20-liasa de testosterona. Expired - Lifetime ES2178750T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60127896A 1996-02-14 1996-02-14

Publications (1)

Publication Number Publication Date
ES2178750T3 true ES2178750T3 (es) 2003-01-01

Family

ID=24406899

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97901995T Expired - Lifetime ES2178750T3 (es) 1996-02-14 1997-01-09 17-beta- iclopropil(amino/oxi)4-aza esteroides como inhibidores activos de la 5-alfa-reductasa y de c17-20-liasa de testosterona.

Country Status (17)

Country Link
EP (1) EP0880540B1 (es)
JP (1) JP2000505444A (es)
KR (1) KR19990082543A (es)
CN (1) CN1211256A (es)
AT (1) ATE219100T1 (es)
AU (1) AU710208B2 (es)
BR (1) BR9708301A (es)
CA (1) CA2244823A1 (es)
DE (1) DE69713285T2 (es)
DK (1) DK0880540T3 (es)
ES (1) ES2178750T3 (es)
HU (1) HUP9900955A3 (es)
IL (1) IL125575A0 (es)
NO (1) NO983724L (es)
NZ (1) NZ327041A (es)
PT (1) PT880540E (es)
WO (1) WO1997030069A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187925B1 (en) * 1997-12-23 2001-02-13 Merck & Co., Inc. Intermediates and process for the synthesis of azasteroids
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
WO2002046186A1 (en) * 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
JP4832303B2 (ja) 2003-05-07 2011-12-07 メルク・シャープ・エンド・ドーム・コーポレイション アンドロゲン受容体モジュレータおよびこれらの使用
SG185930A1 (en) * 2007-10-29 2012-12-28 Takeda Pharmaceutical Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies
WO2010062506A2 (en) * 2008-10-28 2010-06-03 Lead Therapeutics, Inc. Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
WO2011088160A2 (en) * 2010-01-15 2011-07-21 Biomarin Pharmaceutical Inc. Novel cyp17 inhibitors
GB201102913D0 (en) 2011-02-18 2011-04-06 Univ Birmingham Novel therapeutic
CN109438549B (zh) * 2018-12-13 2022-01-04 湖北葛店人福药业有限责任公司 一种制备N-叔丁基-3-氧代-4-氮杂-5α-雄甾-17β-甲酰胺的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264427A (en) * 1992-01-29 1993-11-23 Research Corporation Technologies, Inc. 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
JPH07506575A (ja) * 1992-05-21 1995-07-20 アンドルシェルシュ・インコーポレイテッド テストステロン５α−レダクターゼ活性の阻害剤
US5486511A (en) * 1993-05-25 1996-01-23 Merrell Dow Pharmaceuticals Inc. 4-amino-17β-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17β-(cyclopropylamino)androst-4-en-3-one and related compounds as C17-20 lyase and 5α-reductase

Also Published As

Publication number Publication date
AU710208B2 (en) 1999-09-16
AU1576797A (en) 1997-09-02
DK0880540T3 (da) 2002-10-07
CN1211256A (zh) 1999-03-17
EP0880540A1 (en) 1998-12-02
IL125575A0 (en) 1999-03-12
PT880540E (pt) 2002-10-31
WO1997030069A1 (en) 1997-08-21
ATE219100T1 (de) 2002-06-15
DE69713285D1 (en) 2002-07-18
KR19990082543A (ko) 1999-11-25
BR9708301A (pt) 1999-08-03
HUP9900955A3 (en) 2000-06-28
DE69713285T2 (de) 2003-01-02
NO983724D0 (no) 1998-08-13
HUP9900955A2 (hu) 1999-07-28
CA2244823A1 (en) 1997-08-21
JP2000505444A (ja) 2000-05-09
NZ327041A (en) 1999-11-29
EP0880540B1 (en) 2002-06-12
NO983724L (no) 1998-10-13

Similar Documents

Publication Publication Date Title
UY26472A1 (es) Compuestos de dihidropirimidina heterocíclicos
PA8509901A1 (es) Compuestos, composiciones farmaceuticas de indazol y metodos para mediar o inhibir la proliferacion celular.
MY196582A (en) PD-1/PD-L1 Inhibitors
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
PE20020348A1 (es) Exemestano como agente quimiopreventivo
DK147086D0 (da) Farmaceutisk komposition til kombinationsterapi af hormonafhaengige cancertyper
ES2077675T3 (es) Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos.
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
ES2195382T3 (es) Compuestos indolcarboxilicos y su uso como compuestos farmaceuticos.
MX2010001125A (es) Composiciones incluyendo receptor androgeno de degradacion (ard) ponteciadores y metodos de tratamiento profilactico o terapeutico de trastornos de la piel y la caida de cabello.
GT199900189A (es) Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migraña.
PY2261702A (es) Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus
TR200200066T2 (tr) Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri
ZA201908404B (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
AR029371A1 (es) Urea-peptoides de indol e indazol como antagonistas del receptor de trombina, composicion farmaceutica y el uso.
PH12022551493A1 (en) Synthetic triterpenoids with nitrogen-based substituents at c-17 and methods of use thereof
SV2002000005A (es) Heterociclos 2-arilimino substituidos y composiciones que los contienen para usar como agentes que ligan el receptor de la progesterona ref. 5048p1-sv
NZ327041A (en) 17-beta-cyclopropyl(amino/oxy) 4-aza steriods as active inhibitors of testosterone 5-alpha-reductase and C17-20-lyase
ES2190201T3 (es) Medicamento para la profilaxis y/o el tratamiento del carcinoma de mama que contiene un inhibidor esteroideo de la aromatasa.
JP2019127471A (ja) 美肌用組成物
BR112022009457A2 (pt) Inibidores duplos de receptor androgênico/akr1c3
AR036257A1 (es) Sulfamatos de 2-alcoxiestradiol de accion antitumoral
AR048829A1 (es) 17alfa - fluoroesteroides con actividad inhibidora de 5 alfa-reductasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades cancerosas influidas por androgenos.